Aurobindo Pharma arm’s injectable facility gets product nod from U.S. FDA 

The regulator had inspected the unit in Anakapalli district of Andhra Pradesh from March 28-April 05 

Updated - September 11, 2024 05:52 pm IST - HYDERABAD

A new injectable facility of Aurobindo Pharma’s subsidiary Eugia Steriles has received its first product approval from the United States Food and Drug Administration.

The U.S. FDA inspected the unit in Parawada mandal of Anakapalli district, Andhra Pradesh, from March 28 to April 5. It has now received its first product approval from the U.S. FDA for Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL).

The sANDA (supplemental abbreviated new drug application) was submitted as Prior Approval Supplement for addition of an alternate drug product manufacturing, labelling, packaging and testing facility, Aurobindo Pharma said in a filing on Wednesday.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.